



Eisai India and GSK signed an agreement to co-promote Paritec® (rabeprazole sodium) in India

Mumbai, May 26, 2005: Eisai Pharmaceuticals India Private Limited and GlaxoSmithKline Pharmaceuticals Limited today announced signing of a co-promotion agreement for Paritec® (rabeprazole sodium) in India. Based on this agreement, Eisai India and GSK will co-promote Paritec®.

Paritec® is a proton pump inhibitor discovered and developed by Eisai Co., Ltd. It is approved for the treatment of acid-related disorders like peptic ulcer, reflux gastric disorders (GERD).¹[1] Eisai Co., Ltd. is amongst the top five research-based Japanese pharmaceutical companies in Japan. It is the first Japanese pharmaceutical major to enter India through a 100% subsidiary consequent to the enactment of Patent Act by the country.

S. Kalyanasundaram, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, India and Vice President, South Asia, GSK International, speaking to journalists in Mumbai today, said, "We are pleased to enter into this co-promotion agreement with Eisai to facilitate the launch of Paritec in the Indian pharmaceutical market." He further added, "GSK has a strong presence in the gastro-intestinal market and enjoys immense goodwill among the medical fraternity on account of Zantac. In rabeprazole, we will have an excellent molecule that will effectively fulfill unmet patient needs and allow us offer a product in a high-growth market segment."

Complimenting Mr. Kalyanasundaram on the co-promotion agreement, Hideshi Honda, Executive Officer and Vice President (Global Pharmaceuticals), Eisai Co., Ltd. said, "As a leading research based Japanese pharmaceutical company, we studied the Indian market and decided to launch Paritec (rabeprazole), one of our global block-busters with worldwide sales of 132 Billion Yen. GSK India, with its long presence in the country and undisputed market leadership, qualified as our obvious choice for a partnership." Mr Honda further added, "Eisai is a human health care company. We give our first thoughts to the patients and their families and contribute to increasing their benefits. Establishment of a 100% subsidiary in India and the promotion pact with GSK India, both signal our long term commitment to the country."

About GSK India

GlaxoSmithKline Pharmaceuticals Limited is India's leading research-based Company with a large presence in the domestic pharmaceuticals market with a market share of 6.5 per cent (ORG-IMS Dec 2004). The Company promotes a wide range of ethical formulations and is the leader in therapeutic areas of respiratory, dermatology and vaccines, besides having a significant presence in areas of gastroenterology, dietary supplements, gynecology, neurology, cardiovascular and intensive care. GSK India is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

About Eisai

Eisai is a human health care company that discovers, develops and markets products worldwide. Through a global network of research, manufacturing and marketing operations, the company employs more than 8,000 people and reported sales of 533 billion yen worldwide in FY2004.